Ema committee for medicinal products for human use (chmp) recommends use of the moderna covid-19 booster in adolescents (12-17 years) in the european union

Cambridge, ma / accesswire / july 22, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted a positive opinion recommending a variation to the conditional marketing authorization (cma) to include a booster dose of spikevax, the company's covid-19 vaccine, at the 50 Μg dose level for adolescents (12-17 years) at least three months after completion of the primary series. "the recommendation to authorize the use of a booster dose of spikevax in adolescents ages 12-17 is an important step to continue to protect this age group from covid-19 and the the emergence of new variants of concern," said stÉphane bancel, chief executive officer of moderna.
MRNA Ratings Summary
MRNA Quant Ranking